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Background: Written medicine information can play an important role in educating consumers about their
medicines. In Australia, standardised, comprehensive written information known as Consumer Medicine Information
(CMI) is available for all prescription medicines. CMI is reportedly under-utilised by general practitioners (GPs) and
community pharmacists in consultations, despite consumer desire for medicine information. This study aimed to
determine consumers’, GPs’ and community pharmacists’ preferences for CMI provision and identify barriers and
facilitators to its use.
Method: Structured questionnaires were developed and administered to a national sample of Australian consumers
(phone survey), community pharmacists and GPs (postal surveys) surrounding utilisation of CMI. Descriptive and
comparative analyses were conducted.
Results: Half of consumers surveyed wanted to receive CMI for their prescription medicine, with spoken
information preferable to written medicine information for many consumers and healthcare professionals. GPs and
pharmacists remained a preferred source of medicine information for consumers, although package inserts were
appealing to many among all three cohorts. Overall pharmacists were the preferred provider of CMI primarily due
to their medicine expertise, accessibility and perceived availability. GPs preferred CMI dissemination through both
the GP and pharmacist. Some consumers preferred GPs as the provider of medicines information because of their
knowledge of the patients’ medicines and/or medical history, regularity of seeing the patient and good relationship
with the patient. Common barriers to CMI provision cited included: time constraints, CMI length and perceptions
that patients are not interested in receiving CMI. Facilitators to enhance provision included: strategies to increase
consumer awareness, longer consultation times and counseling appointments, and improvements to pharmacy
software technology and workflow.
Conclusion: Medicine information is important to consumers, whether as spoken, written or a combination of
both. A tailored approach is needed to ascertain individual patient preference for delivery and scope of medicine
information desired so that appropriate information is provided. The barriers of time and perceived attitudes of
healthcare practitioners present challenges which may be overcome through changes to workplace practices,
adoption of identified facilitators, and education about the positive benefits of CMI as a tool to engage and
empower patients.
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Written medicine information plays a pivotal role in
educating consumers about medicines. Evidence sug-
gests that written medicine information may influence
patient knowledge and satisfaction [1], and have a bene-
ficial effect on treatment adherence [2] and other health
outcomes [3]. Written medicine information in the form
of standardized Consumer Medicine Information (CMI)
has been a topic of interest and debate since its in-
troduction in Australia in 1993. Subsequent research
[4,5], reports [6,7] and stakeholder consultations [8]
have sought to gather information surrounding pro-
vision [6,7], utilisation [9,10] and impact [4,11]. Re-
cently, the Therapeutic Goods Administration (TGA)
sought public consultations on clarity around prepar-
ation, approval and maintenance of CMI, and its pur-
pose and function [12].
CMI are standardised, brand-specific written informa-
tion for consumers about prescription and pharmacist-
only medicines prepared by pharmaceutical manufacturers
[13]. CMI must be available to consumers either as a
package insert or in a format enabling the information to
be provided to the end-user of the medicine, for example
electronically through healthcare professional dispensing
or prescribing software, or via the Internet on Govern-
ment and third-party websites [13]. The content must
conform to regulations, but its availability, format and
provision by healthcare professionals is not mandated [14].
Doctors and pharmacists however have a duty of care to
provide medicine information, whether spoken and/or
written, and as such guidelines have been produced
to assist them in their legal and professional obligations
[15-17].
Herxheimer suggested that written medicine infor-
mation, such as CMI should satisfy three main criteria:
firstly, what to expect from the medicine, secondly, how
to use the medicine and lastly assist the consumer in
communicating well with their healthcare professional
about their medicine treatment [18]. Whilst CMI in
Australia aims to address the first two criteria, evidence
suggests CMI is under-utilised in counseling and re-
ceipt rates remain low [6,19]. Prior negative experiences,
such as poor medication adherence after patients read-
ing CMI, may influence perceptions of CMI. This may
cause doctors and pharmacists to feel ambivalent about
CMI provision and its use as a tool in educating con-
sumers [9]. A recent exploratory study found time pres-
sures during consultations, low patient confidence and
communication skills, accessibility and insufficient de-
mand for medicine information were barriers to patient
CMI use [10]. Other studies have investigated pharma-
cists’ utilisation of CMI [7], including perceived obstacles
to provision [5], however none have examined general
practitioner (GP) practices.An understanding of the barriers and facilitators, both
perceived and actual, experienced by healthcare profes-
sionals and consumers in using CMI is necessary for the
development of strategies and policies to promote in-
creased use and better integration of CMI, and similar
information resources, into daily practice. Therefore, in-
formed by the findings of our two previous exploratory
qualitative studies [9,10] on CMI use in Australia, we
conducted a study which aimed to: (1) determine prefer-
ences for CMI provision and (2) identify the barriers and
facilitators to the utilisation of CMI from the perspec-
tives of consumers, GPs and community pharmacists.Methods
Study design
Ethical approval was granted from the University of Syd-
ney Human Research Ethics Committee to conduct this
national study, which consisted of telephone surveys ad-
ministered to consumers and mail surveys for healthcare
professionals (GPs and pharmacists). The study was car-
ried out between February and April 2009.
The consumer questionnaire was administered using a
computer-assisted telephone interviewing system. Con-
sumers were randomly selected from the Australian tele-
phone directory and recruited using a pre-written script
providing study information. Eligible consumers were:
at least 18 years of age, able to participate without
the need for a translator and taking at least one pre-
scription medicine in the month prior to the survey.
Responses were recorded directly into a database dur-
ing the interview.
A random national sample (stratified by state using
Australian Bureau of Statistics (ABS) [20] population data
as the denominator and proportionally represented for
metropolitan and rural populations) of 1100 community
pharmacists and 1100 GPs was collected from a health-
care data information company database. The GPs and
community pharmacists were invited to participate by a
mailed postcard, prior to receiving the study pack contain-
ing study information and the questionnaire. A reminder
and/or thank you postcard was sent two weeks after the
initial survey. To increase response rates and encourage
non-respondents, a further survey pack was sent four
weeks after the initial survey.Sample size
Consumer sampling and recruitment was stratified by
state and territory using ABS [21] population data to
survey a representative sample based on age, gender and
both metropolitan and rural populations. The standard
error of proportions equation was used to calculate the
sample size [22]. Although sample size calculations re-
quired a total of 226 consumers for the telephone survey,
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tive evaluation with a previous study [7].
Specifying a 5% degree of precision, and using a previ-
ously reported proportion of New South Wales (NSW)
pharmacists providing CMI (7.6%) [5] the sample size
for community pharmacists was calculated as 108. As-
suming a 30% response rate, 360 pharmacists were re-
quired within NSW. The number of questionnaires sent
to the remaining states and territories were stratified
using the number of pharmacies per state/territory as
the denominator, giving a total sample distribution of
1046, which was rounded up to 1100 subjects. There
were no published data on the proportion of GPs or
other prescribers providing CMI. Informed by response
rates from other studies with medical practitioners
(range: 47-68% [23,24]), a conservative 30% response
rate was assumed and the GP sample size of 1100 sub-
jects was selected to be consistent with the pharmacist
sample.Questionnaires
The questionnaires were derived from earlier research
[10] and previous findings [7,25]. A central question-
naire was developed and subsequently adapted specific-
ally for each cohort: consumers, GPs and pharmacists.
The structured questionnaires contained close-ended
questions with single or multiple response options. The
results in this paper are drawn from sections of the
questionnaire focusing on two aspects:
 Future provision of CMI.
 Strategies to promote CMI awareness and use.
The questionnaires [6] and results derived from other
sections have been published elsewhere [26].
The questionnaires were reviewed by a panel of pharma-
cists (n = 8), consumer representatives (n = 2) and experts
in the field (n = 9) before piloting with four community
pharmacists (postal questionnaire) and twenty-five con-
sumers (telephone interviews). Based on feedback re-
ceived, minor adjustments were made to the wording of
the questions. Any changes derived from feedback were
reflected across all three questionnaires.
All data were coded and entered into Statistical Pack-
age for Social Sciences (Version 19.0 IBM). Descriptive
and frequency distributions were compiled and exam-
ined for each response before further analysis. Not all
questions were answered and/or some allowed multiple
responses hence the number of respondents varied for
each question. Chi-square analyses comparing the bar-
riers and facilitators and respondent demographic data
were performed although no relevant statistically signifi-
cant data were yielded.Results
Participant demographics
The mail survey response rates were 34% (n = 349) and
17% (n = 181) for pharmacists and GPs, respectively. Re-
searchers conducting the phone surveys called 11,653
telephone numbers nationally in both metropolitan and
rural areas stratified according to ABS [21] demographic
data to obtain the required 1000 eligible and consenting
respondents. Potential participants were telephoned over
a period of 21 consecutive nights between 6 pm and
8 pm local time, and up to five callbacks were made to
establish contact. A total of 5386 persons answered the
phone, of which 2107 people refused to participate with
a further 1644 people not meeting the eligibility criteria,
resulting in a response rate of 32%.
Females represented 52% (n = 516) of consumer re-
spondents, with a median age of 60 (range 18–98) years
and most spoke English as their first language (n = 970,
97%). Fifty-four percent (n = 189) of pharmacists were
female with a median age of 47 (range 22–87) years,
whilst 52% (n = 93) of GPs were female with a median
age of 52 (range 31–83) years. The majority of pharma-
cists spoke English as their first language at home (n =
307, 88%), as did GPs (n = 158, 87%).
The occupations of consumer respondents consisted
of: white-collar workers (n = 343, 34%); retirees (386,
39%); blue-collar workers (121, 12%); homemakers (85,
9%) and student/unemployed (47, 5%). Consumers’ edu-
cation varied with 53% (n = 526) attaining a high school
education, 37% (n = 370) a tertiary education, and the
remaining a certificate or TAFEa qualification. Pharma-
cists reported a median of 23 (Interquartile range (IQR)
7–33) years experience in their profession and primarily
worked in independent (n = 185, 53%), or chain (n = 160,
46%) pharmacies (missing data n = 5). Approximately
half (170, 49%) were owners or partners of the phar-
macy, with the remainder permanent (140, 40%) or cas-
ual (29, 8%) employees. GPs had a median of 25 (IQR
16–31) years of experience and were in group (n = 152,
85%) or sole practices (n = 27, 15%).Preferred source and provider of CMI
Half (n = 500, 50%) of consumer respondents wanted to
receive CMI for their prescription medicines. Consumers
were asked to indicate two preferred sources of medi-
cine information. Package inserts (n = 680, 68%) and
computer-generated information from their doctor or
pharmacist (n = 541, 54%) were reported as the two most
preferred sources. A small proportion favoured informa-
tion from a website (n = 126, 13%) or handwritten medi-
cine information from their doctor or pharmacist (n = 98,
10%) and almost half (n = 435, 44%) only wanted spoken
information from their doctor or pharmacist.
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method of providing medicine information to their
patients. The top three ranked sources by pharmacists
(n = 349) were: CMI printed from the dispensing soft-
ware (39%), spoken information (35%) and package in-
serts (23%). In comparison, GPs (n = 181) ranked spoken
information (41%), package inserts (34%) and CMI
printed from the prescribing software (15%) with some
(14%) equally preferring written medicine information
(other than CMI) from their prescribing software. Least
preferred by pharmacists (1%) and GPs (1%) was to rec-
ommend a website.
Respondents were asked to nominate their preferred
provider of CMI. Table 1 shows comparisons between
GP, pharmacist and consumers responses. Both pharma-
cist (53.8%) and consumer (33.4%) cohorts saw CMI
provision as the pharmacists’ role. In contrast, GP re-
spondents felt the responsibility to provide CMI was
both that of GP and pharmacist (46.4%). Few respon-
dents wanted CMI accessed from the Internet.
The reasons for the allocation of role responsibility
were explored (Table 2). Consumers considered both
pharmacists and GPs as ‘experts in medicines’. They felt
GPs were more aware of their medical history and medi-
cines than pharmacists, however, easy access to and
availability of pharmacists’ time made them attractive as
a source of information, a view shared by both GPs and
pharmacists. Both professions thought GPs as prescri-
bers, should take more responsibility in providing CMI.
Barriers to the provision of CMI
Responses were elicited from the three cohorts about
the reasons for the non-provision of CMI in practice
(barriers) by pharmacists and GPs. In the analysis
these were subsequently categorised as either: situational
(practice-related), financial (remuneration/cost of business),Table 1 Consumer, pharmacist and GP preferences on CMI pr
CMI Provider
Consumer: Who would you like to receive CMI from?
Pharmacist/GP: Where do you think customers/patients should receive th
Pharmacist only
Doctor only
Both doctor and pharmacist
Neither doctor or pharmacist
Package insert
Internet website for CMI
Patients should not receive CMI
Missing value
TOTAL
NA: Not asked.attitudinal (behaviours and perceptions) or cognitive
(awareness, knowledge and understanding), based on
previous research [27].
Table 3 shows the comparisons of the consumer,
pharmacist and GP responses. Acknowledgement of time
pressures was evident in the responses for all cohorts al-
though this was more prominent for GPs. Financial bar-
riers did not feature significantly in either cohort, except if
CMI length was considered an issue for financial reasons
(this distinction was not explored) that would relate to
cost of time/labour and materials. The attitude of pharma-
cists/GPs featured prominently in consumer responses,
most notably over a third of consumers reported that
healthcare professionals think consumers only need to
know what they are told, which makes the assumption
that spoken information is sufficient for the consumer.
Interestingly, the majority of pharmacists (61.3%) and al-
most half of GPs (42.8%) perceived that patients them-
selves are not interested in receiving CMI. The only
cognitive barrier reported by pharmacists and GPs related
to practice policy, and highlighted perhaps a lack of know-
ledge or awareness of professional obligations. This was
more prevalent among GPs than pharmacists. Over a third
of consumers reported CMI might not be provided to
them because of healthcare professional concerns about
their ability to understand the leaflet, which highlights
consumers’ own awareness of issues of literacy and com-
prehensibility with health information.
Facilitators to the provision of CMI
Respondents were also asked their thoughts on what
would promote or facilitate CMI provision (Table 4). Con-
sumer responses (40.4%) indicated that raising awareness
of CMI as an available source of information about
their medicines was a priority to increase CMI provision.
This was reflected to a lesser extent in pharmacist (35%)ovider (role)
Consumer
n = 500 (%)
Pharmacist n = 349 (%)
(Missing n = 25)
GP n = 181 (%)
(Missing n = 20)
eir CMI?
167 (33.4) 188 (53.8) 23 (12.7)
129 (25.8) 5 (1.4) 20 (11.1)
71 (14.2) 98 (28.1) 84 (46.4)
12 (2.4) NA NA
116 (23.2) 32 (9.2) 29 (16.0)
3 (0.6) 0 1 (0.6)
NA 1 (0.3) 4 (2.2)
2 (0.4) 25 (7.2) 20 (11.0)
500 (100) 349 (100) 181 (100)
Table 2 Reasons for role responsibility of the pharmacist or doctor as most appropriate provider of CMI
Why do you think this person (the pharmacist or GP as chosen) is the best person to provide CMI?
Reason Given by respondents
Consumer Respondents Pharmacist Respondents GP Respondents
Pharmacist
n = 167 (%)
GP
n = 129 (%)
Pharmacist
n = 188 (%)
GP
n = 5 (%)
Pharmacist
n = 23 (%)
GP
n = 20 (%)
The doctor/pharmacist is an expert on medicines 110 (65.9) 77 (59.7) 158 (84.0) 1 (20.0) 13 (56.5) 5 (25.0)
The doctor/pharmacist is aware of patient medical history
and/or medicines
16 (9.6) 36 (27.9) 136 (72.3) 4 (80.0) 4 (17.4) 18 (90.0)
The doctor/pharmacist has more time to speak with the patient 19 (11.4) 1 (0.8) 84 (44.7) 1 (20.0) 9 (39.1) 1 (5.0)
The patient is able to access the doctor/pharmacist at any time 12 (7.2) 3 (2.3) 140 (74.5) 0 (0) 8 (34.8) 0 (0)
The doctor/pharmacist is prescribing/dispensing the medicine 11 (6.6) 9 (7.0) 104 (55.3) 4 (80.0) 12 (52.2) 14 (70.0)
The doctor/pharmacist sees the patient on a regular basis 8 (4.8) 9 (7.0) 133 (70.7) 0 (0) 1 (4.3) 10 (50.0)
The patient has a good relationship with the doctor/pharmacist 6 (3.6) 11 (8.5) 129 (68.6) 0 (0) 4 (17.4) 13 (65.0)
The patient is comfortable discussing their medicine with them 2 (1.2) 6 (4.7) 101 (53.7) 1 (20.0) 0 (0) 9 (45.0)
Other 14 (8.4) 2 (1.6) 0 (0) 0 (0) 0 (0) 1 (5.0)
Note: Responses are not mutually exclusive.
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respondents indicating CMI provision should be made
compulsory, this sentiment was not shared by either
GP or pharmacist respondents. Issues of increasing avail-
able time or time saving measures were more prominent
in pharmacist and GP responses. The majority of GPs and
pharmacists indicated that having a summary (shortened
version) CMI would facilitate provision. Over half ofTable 3 Barriers to the provision of CMI reported by GPs and
Barrier
Type
Barriers to the provision of CMI
What do you think are the reasons that you or other (pha
as appropriate) are unable to provide CMI to customers/p
Situational Limited time/too busy
The CMI is not available in other languages
The CMI is too long to print off*
CMI is difficult to provide because of the layout and workflow
Financial There is a lack of printers or printing costs are too high
Attitudinal Think consumers do not need to know more than what they are
Concern consumer may ask too many questions
Patients are not interested in receiving CMI or GP/Pharmacist not
The person is not a regular patient
GP/Pharmacist concerned consumer won’t take the medicine
I am always provided with a CMI
Assume patient already knows about their medicine
It is a repeat prescription
Cognitive Concern information may be difficult to understand/read
It is not the policy of the pharmacy or GP practice
Other No reason/don’t know
Other
*Also considered as a financial barrier.
#Consumer questionnaire omitted “you or other” from the question.
NA: Not asked in questionnaire.
Note: Responses are not mutually exclusive.pharmacists and almost half of GPs wanted more time to
provide and explain CMI, and around a quarter of both
groups wanted counselling appointments to address pro-
vision. In contrast, consumers’ responses showed a de-
cided lack of interest in the increased availability of
healthcare professionals’ time to explain (8.2%) or specific
appointments (0.9%) to discuss CMI, despite over half of








527 (52.7) 196 (56.2) 141 (78.3)
NA 116 (33.2) 41 (22.8)
260 (26.0) 77 (22.1) 111 (61.7)
of the pharmacy NA 27 (7.7) NA
NA 35 (10.0) 29 (16.1)
told by GP/Pharmacist 346 (34.6) NA NA
291 (29.1) NA NA
interested in giving out 177 (17.7) 214 (61.3) 77 (42.8)
224 (22.4) 32 (9.2) 22 (12.3)
155 (15.5) NA NA
25 (2.5) NA NA
18 (1.8) NA NA
9 (0.9) NA NA
345 (34.5) NA NA
NA 24 (6.9) 35 (19.4)
83 (8.3) NA NA
42 (4.2) 45 (12.9) 23 (12.8)
Table 4 Facilitators to the provision of CMI by GPs and pharmacists
Barrier
Type





n = 181What do you think may help you or other pharmacists/GPs to provide CMI
to customers/patients?#
Situational More time to provide and explain CMI 82 (8.2) 184 (52.7) 81 (45.0)
Having a self-serve computer in the pharmacy or surgery to print CMI 10 (1.0) 71 (20.3) 36 (20.0)
Counselling appointments to discuss patients’ medicine 9 (0.9) 86 (24.6) 52 (28.9)
Private area in a pharmacy to discuss the CMI 6 (0.6) NA NA
Having CMI in different languages 6 (0.6) 114 (32.7) 52 (28.9)
Dispensing software prompts to provide and record the provision of CMI NA 164 (47.0) 78 (43.3)
Tick box request by doctor on prescription form for pharmacist to provide CMI NA 173 (49.6) NA
Financial If consumers paid for the CMI/increased reimbursement for provision of CMI 17 (1.7) 190 (54.4) 69 (38.3)
Attitudinal Consumers having a regular pharmacist or doctor 23 (2.3) NA NA
Cognitive Increased consumer awareness and request for CMI 404 (40.4) 122 (35.0) 48 (26.7)
Legislate compulsory provision of CMI 143 (14.3) 0 0
Having a summary CMI covering important points about the medicine 40 (4.0) 259 (74.2) 147 (81.7)
Other Don’t know 145 (14.5) 0 0
Other 91 (9.1) 6 (1.7) 6 (3.3)
#Consumer questionnaire omitted “you or other” from the question.
NA: Not asked.
Note: Responses are not mutually exclusive.
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sponse to financial barriers, both pharmacists and GPs in-
dicated increased reimbursement would facilitate CMI.
Consumer respondents, however were less inclined to
want to pay for CMI.
Finally, a note should be made regarding the chi-
square analyses conducted comparing the barriers and
facilitators and the respondent demographic data. No
statistically significant findings were made in relation to
GPs. Whilst there were some statistically significant
associations relating to pharmacists’ gender, age and ex-
perience (e.g. gender (female) was associated with situ-
ational barrier of ‘CMI not in other languages’ χ2(1) =
5.389, p = 0.020; age (<47 years) and years of experience
of pharmacists (<15 years) with the situational barrier of
‘lack of printers’ χ2(1) = 9.290, p = 0.001 and χ2(2) =
8.673, p = 0.013 respectively) these were not considered
practically meaningful or relevant in the clinical or prac-
tice context.
Discussion
This study identified consumers’, GPs’ and pharmacists’
preferences regarding the source and provider of medi-
cine information, and determined the barriers and facili-
tators to the use of this information, in particular CMI.
The participating consumer sample was closely repre-
sentative of the Australian population. In terms of gen-
der the study contained 52% females, in line with the
nominated sampling frame of 52.5% females. The median
age for consumer participants was 60 years in comparisonto 37 years for the Australian population [20] but this de-
viation could be explained by the specific targeting of
medicine users whose higher median age was not unex-
pected as medication use and proportion of medicines
used increases with age. Notably, the education levels of
consumer respondents varied significantly, particularly the
percentage of participants who held tertiary qualifications
which was higher than ABS [28] reported data (37% vs
23%). This may be because those consumers with a higher
level of education may have read medicine information in
the past and were therefore more interested in participat-
ing in the study.
It is evident from the study findings that consumers
want information about their medicines, each with their
own differing needs and preferences. Healthcare profes-
sionals are still the preferred source of information for
consumers, although a greater desire for package inserts
in comparison to electronic CMI was found. This greater
preference may be because consumers are guaranteed to
receive the information without having to rely on health-
care professionals, or that they are likely to receive a
CMI every time they collect their chronic medications
and so do not need to retain previously received CMI.
Whilst the results indicated that half of consumer re-
spondents wanted to receive CMI, about 44% only wan-
ted spoken information about their medicine. Previous
studies have indicated that patients view written medi-
cine information as a back-up to spoken information [3]
and are even resistant to receiving written information
[29]. Education level may also play a role in determining
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trust in their healthcare professional [10]. All of these
factors may explain why many consumer respondents
only desired spoken information. Additionally, the find-
ings may also reflect the preferences of the doctors and
pharmacists, who favoured providing spoken informa-
tion. Spoken information is easier to deliver especially
where time is a barrier, and can be tailored to consumer
needs. In addition, healthcare professionals may at times
have (legitimate) concerns regarding consumers’ capacity
to understand CMI and as such may elect to provide
only spoken information. This may restrict the number
of CMI being delivered, diminish consumer-healthcare
professional interaction and limit consumer awareness
of CMI. Whilst this may be justifiable (acknowledging
CMI may not be the most appropriate information source
for all consumers), the use of CMI as a counseling tool
has many potential positive benefits that may result in en-
hanced patient familiarity and confidence with CMI, may
increase its readership and use, and further empower pa-
tients with increased knowledge about their medicines.
In the least, CMI should be an option offered at each
consultation.
An important factor in determining where information
is sought is access [31]. Pharmacists were preferred as a
source of information over doctors. Pharmacists ap-
peared to be perceived as ‘medicines experts’ by all co-
horts, and were seen to be considerably more accessible
to consumers and with time available (although pharma-
cists themselves did report time as a considerable barrier
to provision). Pharmacists are frequently the last practi-
tioner the patients may see before commencing treat-
ment and their easy access and apparent ability to spend
time with consumers without making an appointment
makes them an attractive source of CMI. Further, profes-
sional obligations surrounding the provision of CMI,
linked to remuneration contained within dispensing fees,
may also explain why pharmacist respondents consid-
ered their profession as the preferred source of CMI.
In contrast, GPs predominantly saw both the doctor
and pharmacist as having responsibility for providing
CMI. GPs were selected by all three cohorts as a pre-
ferred provider of CMI predominantly because of their
understanding and knowledge of patients’ medical his-
tory and/or medicines, regularity of seeing the patient,
and their good relationship with the patient. The role of
the doctor could be seen as ‘decision-maker’ due to be-
ing initiator of treatment and prescriber of medicines,
and as such consumers want CMI at the time of pre-
scribing or during consultation, as previously noted in
the literature, for use in risk-benefit analysis, informed
decision-making and for reassurance [4,10]. Of concern
is the fact that only a small proportion of GP respon-
dents saw themselves as a sole source of CMI whichcould mean that many consumers are missing out on re-
ceiving CMI, and although providing CMI to patients
may not guarantee its use by consumers it may initi-
ate a patient-professional dialogue about the medicine
treatment.
Our results suggest patients may benefit from the clarifi-
cation of role responsibility surrounding CMI provision.
Informing patients about their medicine should be a
collaborative and coordinated approach by both doctor
and pharmacist determined within an inter-professional
context to ensure comprehensive communication by all
healthcare professionals during consultations and receipt
of adequate information by patients about their medicines
so that vital information is not missed. In addition, the un-
derstanding of healthcare professional roles in CMI
provision may positively address reported time constraints
and avoid gaps in information provision through diffusion
of responsibility.
A surprise finding was how few respondents indicated
a preference for the Internet as a source of written medi-
cine information, considering the reportedly increasing
use of the Internet to search for health and medicine in-
formation [32] and the increasing number of online
CMI sources. Other studies have reported the Internet
as a lesser source of information in comparison to doc-
tors and pharmacists, and followed by written medicine
information [33]. Although measures have been intro-
duced in Australia to improve access to CMI through
TGA and various third party provider websites, a lack
of awareness by consumers of up-to-date, reliable and
evidence-based Internet sources of information is evi-
dent. Issues of reliability and readability of information,
and the ability to locate information sought on the Inter-
net may be hampering its uptake by consumers [34,35].
The three major barriers to providing CMI to patients
reported by GP and pharmacist respondents were lim-
ited time, the length of CMI and believing patients are
not interested in receiving CMI. Pharmacists also ex-
pressed concerns regarding CMI not being available in
other languages. Time constraints were also a barrier for
consumers, however they reported healthcare profes-
sionals’ attitudes of consumers only needing to know
what they are told and concerns surrounding compre-
hension of CMI as the main barriers to CMI delivery to
consumers. In terms of facilitators, consumers consid-
ered increased awareness about CMI with a more pro-
active approach by consumers to request CMI as the
most important facilitator. A second important facili-
tator for consumers was to legislate compulsory CMI
provision (whether as a pack insert or by healthcare pro-
fessionals was not determined). For GP and pharmacist
respondents, strategies to facilitate CMI provision re-
volved around situational factors such as CMI in differ-
ent languages, dispensing software prompts and in the
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communicate their desire for CMI to be provided to the
patient. Pharmacist and GP respondents did rank a sum-
mary CMI highly, although this was not reflected in con-
sumer responses perhaps because consumer respondents
believed this would mean less information. Lastly, the
GP and pharmacist cohorts highlighted financial faci-
litators through increased remuneration, however con-
sumers did not appear keen to pay for CMI.
As previously noted, the primary situational barrier to
CMI provision was limited time, a point highlighted by
all cohorts, which can have implications for the dis-
semination of CMI. Consultation length may influence
patient understanding, satisfaction and desire for writ-
ten medicine information [10,36]. Given sufficient time,
practitioners have the opportunity to explore patient be-
liefs and preferences, and provide suitable written medi-
cine information to their patients, and tailor the written
information with verbal advice. In practical terms, in-
creased consultation times may not be sufficient or
possible, even though this was a significant situational
facilitator reported in this study. It is virtually impossible
given the current demands on practitioners to deal with
chronic conditions and increasingly complex medicine
regimes to firstly ascertain the appropriate amount of
time for each patient’s situation and secondly spend the
time necessary to discuss in detail the CMI content for
each medicine. Notwithstanding, implementing strat-
egies such as specific appointments to discuss patients’
medicines, broadening of paid medicine reviews, and de-
livery and reinforcement of information by all healthcare
professionals involved in the care of a patient, may partly
address the time burden on practitioners. Situational fa-
cilitators such as increasing efficiency to practice through
upgrading of resources i.e. technical support and software,
and changes to process to improve time management
such as CMI workflow strategies, increased staffing, and
in the case of pharmacists automated dispensing systems,
may address and alleviate time pressures. The implemen-
tation of educational programs for healthcare profes-
sionals on the use of CMI in practice may also address the
attitudinal barriers to CMI highlighted in this study and
assist in its acceptance and adoption in everyday practice
[5]. Furthermore, implementing the cognitive facilitators
suggested in this study such as increasing consumer
awareness through education campaigns and having a
summary CMI as desired by pharmacists and GPs,
may encourage CMI dissemination, foster the patient-
professional dialogue and assist consumers to feel com-
fortable asking for CMI. Introducing a summary CMI
may attend to the issues of CMI length, increase distribu-
tion and use by healthcare professionals, and effect con-
sumer readership, as demonstrated in previous studies
[37,38]. However, finding the balance between concisenessand detail may prove more difficult, with many studies in-
dicating that patients, when given a choice, prefer ex-
panded rather than brief information [3].
Although consumers also saw limited consultation
time as a barrier, their perceptions of the attitudinal bar-
riers affecting provision of CMI by doctors and pharma-
cists were noteworthy. Consumer respondents felt that
doctors and pharmacists limited the amount of medicine
information they provided to patients, which might be
perceived as paternalistic or even withholding informa-
tion. Whilst this may not be the intent of the practi-
tioners in our study, limiting of information may be due
to consideration of and concern for the psychological
cost (anxiety, fear, worry) of patients reading about side
effects and the potential for subsequent non-adherence
[39]. Consumers also thought that doctors and pharma-
cists did not welcome questioning about CMI and their
medicines. Many of these consumers may have wanted
to engage in shared decision-making with their provider
but felt the attitude of their provider precluded them
from asking questions. Of recent years, there has been a
change in the patient-provider relationship shifting from
paternalism towards increasing patient autonomy. Doc-
tors and pharmacists despite supporting patient auton-
omy may struggle with changing roles and the perceived
undermining of their expertise and judgment as patients
increasingly access medicine information and become
involved in their treatment decisions [9].
Health care professionals may also underestimate con-
sumers desire for information [40], which is consistent
with our findings showing a large proportion of GP and
particularly pharmacist respondents reporting consumers
as not interested in receiving CMI, this was despite half of
consumer respondents indicating they would like to re-
ceive CMI for their prescription medicines. Patients have
a right to information and using CMI as a tool may foster
useful discussion, encourage patient engagement with
their treatment decisions and potentially improve their
health literacy.
In interpreting the study findings, the following limita-
tions should be considered. There may be bias towards
participants with a specific interest in CMI, and the
results have been derived from self-report data, and sub-
ject to personal, social desirability and/or recall bias. A
representative consumer sample was achieved with re-
gard to gender and location in accordance with ABS
data, however, there was a greater proportion of partici-
pants with tertiary qualifications, and as would be ex-
pected, a higher proportion of older consumers. Details
of the consumer participants’ current medications and/
or medical conditions were not elicited and their res-
ponses may have been influenced by the seriousness or
chronic nature of their treatment. The telephone surveys
despite the advantages of rapid data collection and
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Inattentiveness, time constraints and survey length may
have a negative affect on participant responses. Calls
were limited to unrestricted landlines, and consumers
with mobile telephones only or silent numbers may not
have been represented. Additionally, respondents may
have used call screen technology to avoid telemarketing
calls and as such did not respond to the telephone call.
The telephone survey response rate was unable to be
compared to the previous telephone survey about CMI
conducted by Benton et al. [7] as no response rates were
provided. However, the study response rate is within the
range of similar public telephone surveys in Australia
which yielded response rates of 18.2% [42] and 47.9%
[43] even when mobile phones [42,43], unlimited call cy-
cles, and weekend/evening call times [42] were included.
Disappointingly, GP response rates were lower than ex-
pected, despite follow-up, which may reflect the low
priority that CMI has for invitees or time pressures
experienced. Although the GPs’ and pharmacists’ re-
spondent sample was not generalisable, the results may
provide fresh insight into the use and provision practices
of GPs and pharmacists in relation to CMI, providing a
basis from which to direct further research.
Conclusion
Doctors and pharmacists are still a preferred source of
medicine information for consumers, despite the rapid
expansion and increasing availability of CMI on the
Internet. It is evident consumers want to receive infor-
mation about their medicines and, whilst this study
found healthcare professionals and many consumers
often prefer spoken information, one in two consumers
still want to be provided with CMI. Discussions with
consumers surrounding the provision of information
should be encouraged so that doctors and pharmacists
may ascertain consumer preference for either spoken,
written or a combination of both types of information
and tailor this according to consumer needs. At the mi-
nimum consumers should receive spoken information
about their medicines as low literacy or education may
preclude them from effectively using CMI.
Whilst concerns regarding length of CMI, and time
limitations as barriers to provision of CMI are valid, im-
provements to the CMI quality and length, and im-
plementing systems into practice that encourage CMI
provision may be of benefit. Addressing time limitations
may be more challenging due to the increasing burden
on healthcare professionals to manage increasingly com-
plex and chronic conditions within limited consultation
times, however targeted questioning, a collaborative inter-
professional environment surrounding role responsibility
and the implementation of healthcare professional educa-
tion and/or on using CMI as a tool during consultationsmay ensure consumers are at the minimum being offered
CMI and/or provided with direction to where CMI may
be accessed at a later point should consumer preference
for this information change. The findings pertaining
to the barriers and facilitators offer an opportunity
for improvements to workflow and time management
in practice, and should be considered as the basis for
future recommendations.
Endnote
aTechnical and Further Education (TAFE) is vocational
education and training offering nationally recognized
qualifications including Certificates, Diplomas, Advanced
Diplomas, Graduate Certificates and Graduate Diplomas.
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